Ortivus
Logotype for Ortivus

Ortivus (ORTI) investor relations material

Ortivus Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Ortivus
Q2 2026 earnings summary25 Aug, 2026

Executive summary

  • Net sales for April–June 2026 decreased by 2% year-over-year to SEK 19.3 million, while gross margin dropped to 37% from 51% due to increased hardware sales and replacements.

  • EBITDA improved to SEK -2.8 million from SEK -4.7 million, and net profit after tax was SEK -3.6 million, up from SEK -6.5 million in the prior year.

  • For January–June 2026, net sales rose 8% year-over-year to SEK 40.8 million, with a gross margin of 42% (down from 46%).

  • The company continues to invest in its MobiMed platform, expanding SaaS offerings and entering new markets such as Australia.

Financial highlights

  • April–June 2026 net sales: SEK 19.3 million (down 2% year-over-year); gross margin: 37% (down from 51%).

  • EBITDA: SEK -2.8 million (improved from SEK -4.7 million); net profit after tax: SEK -3.6 million (improved from SEK -6.5 million).

  • January–June 2026 net sales: SEK 40.8 million (up 8% year-over-year); gross margin: 42% (down from 46%).

  • Cash and cash equivalents at period end: SEK 6.7 million (up from SEK 1.6 million year-over-year).

  • Equity ratio improved to 24% from -26% year-over-year.

Outlook and guidance

  • Continued investment in MobiMed platform, with new SaaS applications and expansion into Australia and other English-speaking markets.

  • Transition to semi-annual financial reporting; next report will be the 2026 year-end report.

  • No formal forecasts provided; forward-looking statements subject to risks and uncertainties.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Ortivus earnings date

Logotype for Ortivus
Q4 202619 Feb, 2027
Ortivus
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Ortivus earnings date

Logotype for Ortivus
Q4 202619 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Ortivus AB is a Swedish medical technology company developing and commercializing solutions for healthcare industry. The Company's solutions are based on its proprietary technologies developed to improve the workflow efficiency in clinical laboratories, as well as reduce costs in organizations that provide diagnostic healthcare services.